Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
China to Soon Decide Whether to Arrest Detained Japanese Astellas Employee
An employee of Astellas Pharma taken into custody in Beijing earlier this year on spying allegations has been placed under criminal detention, it was learned on September 20. Chinese authorities are expected to shortly make an official decision on whether…
To read the full story
Related Article
- Astellas Employee Did Not Appeal, Prison Sentence Finalized in China
July 29, 2025
- Astellas Employee Won’t Appeal China Espionage Sentence
July 22, 2025
- Astellas Employee Sentenced to 3.5 Years in China for Spying
July 17, 2025
- Verdict Due July 16 for Astellas Employee Detained in China
July 14, 2025
- Japan Will Persistently Urge China to Release Detained Astellas Employee: Govt
April 12, 2024
- 1 Year on, China Mulling Potential Indictment of Detained Astellas Employee
March 22, 2024
- Japan Ambassador Meets Astellas Employee Detained in China
November 29, 2023
- China Formally Arrests Astellas Employee, Japan Urges Immediate Release
October 20, 2023
- Japan Embassy Granted First In-Person Visit to Detained Astellas Employee
July 24, 2023
- Japan Industry Frets Fate of Astellas Worker Held in China for Espionage Allegation
March 28, 2023
REGULATORY
- LDP, Ishin Seal Social Security Deal, Set Course for Chuikyo Reform
July 8, 2026
- LDP Lawmakers Renew Calls to Reflect Inflation in Drug Prices
July 8, 2026
- LDP’s New Diabetes Caucus to Push Patients’ Social Participation
July 8, 2026
- LDP, Ishin Near Deal on Chuikyo Reform to Bolster Drug Discovery
July 7, 2026
- Govt Eyes Honebuto Revisions on Biosimilars, MFN Policy
July 7, 2026
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…